bioMérieux Logo

bioMérieux

Provides in vitro diagnostic solutions for clinical and industrial microbiology.

BIM | PA

Overview

Corporate Details

ISIN(s):
FR0013280286 (+13 more)
LEI:
549300AK8Y0LBIQ4T071
Country:
France
Address:
376 CHE DE L'ORME, 69280 MARCY-L'ETOILE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

bioMérieux is a global leader in the field of in vitro diagnostics, dedicated to improving public health worldwide. Since its founding in 1963, the company has developed and provided comprehensive diagnostic solutions—including systems, reagents, software, and services—that enable critical decision-making for clinicians and industrial quality control professionals. The company's activities are focused on two primary areas: clinical diagnostics and industrial microbiology. In the clinical market, its solutions support the diagnosis of infectious diseases, management of sepsis, cardiovascular emergencies, and antimicrobial stewardship. For industrial applications, bioMérieux offers microbiological testing solutions to ensure the safety and quality of food, pharmaceutical, and cosmetic products. The portfolio features advanced systems like BIOFIRE® (multiplex PCR), VITEK® (microbial identification), and BACT/ALERT® (automated blood culture) to deliver rapid and reliable results.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-02 15:44
Novembre 2025 - Déclaration sur le nombre d'actions composant le capital social…
French 108.1 KB
2025-11-04 11:17
Octobre 2025 - Déclaration sur le nombre d'actions composant le capital social …
French 108.2 KB
2025-09-02 11:11
Août 2025 - Déclaration sur le nombre d'actions composant le capital social et …
French 106.1 KB
2025-08-05 09:41
Juillet 2025 - Déclaration sur le nombre d'actions composant le capital social …
French 105.8 KB
2025-06-16 07:01
bioMérieux strengthens its next-generation sequencing capabilities with the acq…
English 222.9 KB
2025-06-16 07:01
bioMérieux renforce ses capacités de séquençage de nouvelle génération avec l’a…
French 248.3 KB
2025-06-03 16:05
Mai 2025 - Déclaration sur le nombre d'actions composant le capital social et s…
French 106.1 KB
2025-06-03 07:01
bioMérieux launches cutting-edge equine infectious respiratory disease testing
English 276.4 KB
2025-06-03 07:01
bioMérieux lance un test diagnostic innovant pour détecter les maladies respira…
French 274.0 KB
2025-05-05 11:37
Avril 2025 - Déclaration sur le nombre d'actions composant le capital social et…
French 106.1 KB
2025-04-22 07:01
WATCHFIRE™ by bioMérieux: a PCR test to detect viruses and bacteria in wastewat…
English 277.8 KB
2025-04-22 07:01
WATCHFIRE™, un nouveau test PCR développé par bioMérieux pour détecter les viru…
French 267.8 KB
2025-04-17 07:01
bioMérieux – First-Quarter 2025 Business Review
English 325.6 KB
2025-04-17 07:01
bioMérieux – Information financière du 1er trimestre 2025
French 281.7 KB
2025-04-07 07:01
bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solutio…
English 276.6 KB

Automate Your Workflow. Get a real-time feed of all bioMérieux filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for bioMérieux

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for bioMérieux via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-09-04 N/A Other Sell 1,432 137,517.82 EUR
2023-09-04 N/A Other Sell 1,253 120,328.10 EUR
2023-09-01 N/A Other Other 2,900 N/A
2023-06-23 N/A Other Other 323 24,971.13 EUR
2023-06-23 N/A Other Buy 323 24,971.13 EUR
2023-06-23 N/A Other Buy 300 23,193.00 EUR
2023-06-23 N/A Other Buy 25 1,932.75 EUR
2023-03-23 N/A Other Sell 16,500 1,650,415.80 EUR

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Develops medical devices, diagnostics, nutritionals, and pharmaceuticals for global health.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900

Talk to a Data Expert

Have a question? We'll get back to you promptly.